SWOG clinical trial number
S1918

A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements

Closed
Phase
Accrual
32%
Abbreviated Title
Ph II/III study of R-miniCHOP +/- oral aza in elderly with newly diganosed DLBCL
Status Notes
Effective 4/24/2026, S1918 has been permanently closed to accrual.
Activated
03/19/2021
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Lymphoma

Treatment

Cyclophosphamide Prednisone Vincristine Doxorubicin Filgrastim Rituximab Pegfilgrastim CC-486 CHOP

Other Study Materials

Eligibility Criteria Expand/Collapse

* See S1918 protocol Section 5.0; accessible from the CTSU protocol abstract page at www.ctsu.org.

Publication Information Expand/Collapse

2023

S1918: Phase II/III study of R-miniCHOP +/- oral azacitidine in participants age 75 years or older with diffuse large B cell and related lymphomas

E Brem;H Li;A Beaven;P Caimi;L Cerchietti;R Olin;NL Henry;H Dillon;R Little;M LeBlanc;B Kahl;J Leonard;JW Friedberg;S Smith Hematology Oncology Vol 41 Issue S2; ICML (June 13 to June 17, 2023, Lugano, Switzerland), publication only

2022

SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas – Aiming to improve therapy, outcomes, and validate a prospective frailty tool

E Brem;H Li;A Beaven;P Caimi;L Cerchietti;A Alizadeh;R Olin;NL Henry;H Dillon;R Little;C Laubach;M LeBlanc;JW Friedberg;S Smith Journal of Geriatric Oncology, Mar;13(2):258-264

PMid: PMID34686472 | PMC number: PMC9879719

2021

S1918: A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements

E Brem;H Li;A Beaven;P Caimi;L Cerchietti;A Alizadeh;R Olin;NL Henry;H Dillon;R Little;C Laubach;M LeBlanc;J Friedberg;S Smith American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), TIPs poster, #3565

Other Clinical Trials

SWOG Clinical Trial Number
S2506

MOZART MZL: A Randomized Phase II Study with a Common Control Arm of Mosunetuzumab Monotherapy Evaluated Against Two Experimental Treatment Arms of Either Combination Mosunetuzumab and Zanubrutinib or Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma
Research Committee(s)
Lymphoma
Activated
08/18/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA4232

A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Research Committee(s)
Lymphoma
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
69%
Open
Phase